Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia

A B S T R A C T Antithrombotic therapy (anticoagulation or antiplatelet therapy) is frequently prescribed in cancer patients for prior or new indications such as venous thromboembolism, secondary prevention of arterial thrombosis or atrial fibrillation. Therefore, it is not uncommon for thrombocytop...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis research 2020-07, Vol.191, p.S68-S73
Main Authors: Leader, Avi, Gurevich-Shapiro, Anna, Spectre, Galia
Format: Article
Language:English
Subjects:
Anticoagulation
Antiplatelet therapy
Atrial fibrillation
Cancer
Thrombocytopenia
Venous thromboembolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A B S T R A C T Antithrombotic therapy (anticoagulation or antiplatelet therapy) is frequently prescribed in cancer patients for prior or new indications such as venous thromboembolism, secondary prevention of arterial thrombosis or atrial fibrillation. Therefore, it is not uncommon for thrombocytopenic cancer patients to have an indication for antithrombotic therapy. Thrombocytopenia does not reduce the risk of recurrent thrombosis. The bleeding risk with anticoagulation appears to increase when platelets are
ISSN:0049-3848
1879-2472
DOI:10.1016/S0049-3848(20)30400-X